The human papillomavirus (HPV) vaccine is pivotal in preventing HPV-related cancers, yet vaccine uptake rates vary significantly. This study assesses the efficacy of parent-adolescent dyad and parent-centered interventions on enhancing HPV vaccine uptake across different doses and over time. The study systematically searched Cochrane, PubMed, Web of Science, and Scopus databases between June 2023 and August 2023. It assessed HPV vaccine uptake among girls aged 9–18 years after parent or parent-adolescent dyad interventions, alongside completion rates. Meta-analyses, utilizing random-effects models, were conducted for each outcome. For the first dose, parent-adolescent dyad interventions indicated a potential, though uncertain, increase in uptake (odds ratio OR 1.43, 95% confidence interval CI: 0.84, 2.42), while parent-centered interventions showed a significant, consistent improvement (OR 1.14, 95% CI 1.08, 1.19). The second dose benefited markedly from dyad interventions (OR 3.75, 95% CI 1.04, 13.52), with parent-centered interventions also demonstrating effectiveness (OR 1.27, 95% CI 1.08, 1.48). For doses three and above, dyad interventions suggested a strong impact (OR 1.77, 95% CI 1.13, 2.77), albeit with variability for parent-centered strategies (OR 1.13, 95% CI 0.41, 3.11). Over time, interventions consistently improved uptake, particularly notable at 6 and 12 months for initial doses and showing long-term improvements in completing the series. The study underscores the differential yet significant impact of parent-adolescent dyad and parent-centered interventions on HPV vaccine uptake across various doses and over time. These findings highlight the importance of tailored, dynamic public health strategies that engage both parents and female adolescents aged 9–18 years to enhance HPV vaccination rates, supporting broader efforts to mitigate HPV-related health outcomes.
Bhengu et al. (2026) studied this question.